Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 2/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | DLAT | P10515 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | SQLE | Q14534 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1786418 | 1.00 | CNR2 (0.34) | CNR2ALOX15CYP3A4KMT2AMEN1 | |
| SCHEMBL13949346 | 1.00 | CNR2 (0.34) | CNR2ALOX15CYP3A4KMT2AMEN1 | |
| SCHEMBL14364476 | 1.00 | CNR2 (0.34) | CNR2ALOX15CYP3A4KMT2AMEN1 | |
| SCHEMBL13949343 | 1.00 | CNR2 (0.34) | CNR2ALOX15CYP3A4KMT2AMEN1 | |
| SCHEMBL13949344 | 1.00 | CNR2 (0.34) | CNR2ALOX15CYP3A4KMT2AMEN1 | |
| SCHEMBL30312097 | 0.84 | CNR2 (0.38) | CNR2 | |
| SCHEMBL2210373 | 0.83 | CNR2 (0.30) | CNR2SQLE | |
| SCHEMBL21971114 | 0.83 | CNR2 (0.30) | CNR2 | |
| SCHEMBL14603679 | 0.80 | — | — | |
| SCHEMBL3953711 | 0.76 | TRPA1 (0.34) | CYP3A4MAPTPTGESNR1I2DLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287297-B2 | Epoxyazulene derivatives useful for treating cancer and diabetes | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180127433-A1 | EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER AND DIABETES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN (US) | 2018-05-10 | — | — | US | disclosed |
| US-8450533-B2 | Cyclopropanation process | GIVAUDAN SA (CH) | 2013-05-28 | — | — | US | disclosed |
| US-20110124924-A1 | Cyclopropanation Process | GIVAUDAN SA (CH) | 2011-05-26 | — | — | US | disclosed |
| WO-2009023980-A1 | CYCLOPROPANATION PROCESS | GIVAUDAN SA (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20090016976-A1 | CITRAL AND CITRONELLAL DERIVATIVES | FLEXITRAL INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090016976-A1 | CITRAL AND CITRONELLAL DERIVATIVES | FLEXITRAL INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20070276152-A1 | Aromachemicals | FLEXITRAL, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070264340-A1 | Aromachemicals | FLEXITRAL, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070259042-A1 | Cyclopropanated Aromachemicals | FLEXITRAL, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-7169930-B2 | Analogs of epothilone | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090016976-A1 | CITRAL AND CITRONELLAL DERIVATIVES | TAS2R5, TAS2R8, OXGR1 | CNR2 418/4885ALOX15 945/4885CYP3A4 851/4885 |
| US-10287297-B2 | Epoxyazulene derivatives useful for treating cancer and diabetes | ESRRA, ESRRB, ESRRG | CNR2 1429/4885ALOX15 38/4885CYP3A4 565/4885 |
| US-20070276152-A1 | Aromachemicals | TAS2R1, OR10J3, TAS2R4 | CNR2 430/4885ALOX15 1288/4885CYP3A4 95/4885 |
| US-20110124924-A1 | Cyclopropanation Process | CBR3, CYP4F3, DBF4 | CNR2 134/4885ALOX15 286/4885CYP3A4 53/4885 |
| US-20070264340-A1 | Aromachemicals | OR10J3, CBR3, OR51E2 | CNR2 451/4885ALOX15 572/4885CYP3A4 37/4885 |
| US-20070259042-A1 | Cyclopropanated Aromachemicals | CBR3, OR10J3, OR51E2 | CNR2 110/4885ALOX15 507/4885CYP3A4 22/4885 |
| US-20180127433-A1 | EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER AND DIABETES | ESRRA, ESRRB, ESRRG | CNR2 1429/4885ALOX15 38/4885CYP3A4 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.